Remove Immunity Remove Magazine Remove Packaging
article thumbnail

Bharat Biotech acquires licence for GSK’s Shigella vaccine development

Pharmaceutical Technology

The technology utilises outer membrane vesicles (OMVs) to deliver antigens, often eliminating the need for adjuvants while triggering the immune response. Can pharma tariffs “Make America Manufacture Again”? Give your business an edge with our leading industry insights.

article thumbnail

EC approves argenx’s efgartigimod alfa for CIDP treatment

Pharmaceutical Technology

The European Commission (EC) has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous injection to treat adults with chronic inflammatory demyelinating polyneuropathy (CIDP), an immune-mediated neuromuscular disorder of the peripheral nervous system. Can pharma tariffs “Make America Manufacture Again”?

52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Juvenescence enhances AI drug discovery with Ro5 acquisition

Pharmaceutical Technology

This integration will reinforce Juvenescence’s pipeline in cardio-metabolism, cognition, immunity and cellular repair sectors. Can pharma tariffs “Make America Manufacture Again”? Incorporating Ro5’s AI platform into Juvenescence is expected to accelerate the development of AI-enabled treatments.

article thumbnail

Harbour BioMed partners Otsuka on new T-cell therapy

Pharmaceutical Technology

June 23, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook HBM7020 activates immune system T cells to target and destroy B cells and plasma cells involved in many autoimmune diseases. Can pharma tariffs “Make America Manufacture Again”? Credit: luchschenF /Shutterstock.

52
article thumbnail

Novo Nordisk signs $812m research deal with Deep Apple for non-GLP-1 drugs

Pharmaceutical Technology

The biotech used these funds to establish a pipeline that includes three metabolic disease programmes, with further assets across immune disorders and endocrine diseases. Can pharma tariffs “Make America Manufacture Again”? Apple Tree Partners founded the Deep Apple in 2022, investing $52m in series A funding.

article thumbnail

Enterome to advance EO2463 immunotherapy with $19m funding

Pharmaceutical Technology

By GlobalData Learn more about Strategic Intelligence By covering a wide range of targets on malignant B cells, the therapy aims to enhance safety and efficacy while minimising the potential of tumour cells for developing immune-resistance mechanisms such as antigen escape. Can pharma tariffs “Make America Manufacture Again”?

article thumbnail

NSW government invests $13.39m in life-changing therapies

Pharmaceutical Technology

Find out more This treatment involves obtaining immune cells from patients, modifying them in a laboratory setting then reintroducing them into patients’ bodies to destroy cancerous cells. Can pharma tariffs “Make America Manufacture Again”? Data Insights The gold standard of business intelligence.